Rhinomed Limited is pleased to report that it has finalised an exclusive supply agreement with SureScreen Australia to supply Rhinoswabs and Rhinoswab Juniors for inclusion in SureScreen’s class-leading range of lateral flow point of care test kits in the Australian, New Zealand, Singapore and South Pacific markets. The first product to market will be the … Read more
Rhinomed has received an initial purchase order for one million Rhinoswabs from the Victorian Department of Health (DH) to support Victoria’s testing capability. This follows the recent NSW Health Pathology order of one million Rhinoswabs as announced on 11 August. Rhinomed’s Rhinoswab technology improves the sample collection process. As previously disclosed the Rhinoswab is substantially … Read more
Rhinomed has created the world’s first nasal swab designed specifically for children — The Rhinoswab Junior™ Ethics approval has been received for a clinical trial to commence with the Murdoch Children’s Research Institute (MCRI) at The Royal Children’s Hospital in Melbourne Trial seeks to further validate the child-friendly Rhinoswab Junior™ as a safe and effective alternative … Read more
Rhinomed has received purchase orders and begun supplying NSW Health Pathology with an initial one million Rhinoswabs as part of their program to support testing capability. The company has commenced deliveries with these initial orders being fulfilled over coming weeks. Rhinomed is now scaling up its manufacturing facilities to respond to growing domestic and international … Read more
Rhinomed is pleased to announce it has been advised by Medical Device Safety Service GmbH (MDSS) that an Authorized Representative’s Mandate according to the EU Regulation 2017/745 (MDR) is in place. As a result, Rhinomed has been issued a CE Certificate No.: 431330 for the new Rhinoswab. The successful registration and conformity with the relevant … Read more
Rhinomed is pleased to announce the appointment of Associate Professor John McBain AO as a Non Executive Director of the Company, effective immediately. Assoc. Prof. McBain is the former Head of Reproductive Services at The Royal Women’s Hospital in Melbourne, Australia. He is also the former President of the Fertility Society of Australia, and was … Read more
Rhinomed is pleased to report an important update on its Rhinoswab™ clinical program. In December 2020 the company established that the Rhinoswab was comparable to existing standard of care nasal swabs in detecting the SARS-CoV-2 virus in RT-PCR testing. This study was undertaken at the VIDRL (Peter Doherty Institute). Since December the company has further … Read more
Rhinomed is pleased to announce that the Australian Taxation Office has of today’s date refunded the R&D tax incentive amount in respect of the FY20 income tax year. The Company had previously lodged an application with AusIndustry which was approved. The Company then submitted its FY20 tax return, detailing the R&D tax incentive refund amount. … Read more
Rhinomed is pleased to provide its report for the half year ended 31 December 2020. Commenting on the results, Rhinomed’s CEO Michael Johnson said “2020 produced unheralded uncertainty in all of our major markets, despite this Rhinomed continued its strong focus on delivering value to our customers, clinicians and retail partners right across the world. … Read more
Rhinomed is pleased to report positive data from its lab-based spiking study of Rhinomed’s new Rhinoswab conducted at the Victorian Infectious Diseases Reference Laboratory (VIDRL), part of The Peter Doherty Institute for Infection and Immunity (The Doherty) in Melbourne. The study’s objective was to demonstrate efficacy in detecting the SARS-CoV-2 virus at both low and … Read more
Rhinomed has successfully registered its easy to use, high load capturing, comfortable nasal swab with the Australian Therapeutic Goods Administration (TGA) as a Class 1 device. The new swab can comfortably collect samples from both nostrils simultaneously to test for the presence of upper respiratory tract diseases including influenza and coronavirus including SARS-CoV-2. The unique … Read more
Rhinomed Limited is pleased to announce that it has successfully registered its novel nasal swab with the US FDA as a Class 1 device to collect samples from the nose to detect upper respiratory tract diseases including influenza and coronavirus strains. The successful registration and conformity with the relevant standards means that Rhinomed’s novel nasal … Read more
